Evidence × user reports · 44 peptides · checked 13 Nov 2026

Peptides, graded and counted.

Peptide Ledger keeps two columns for every peptide people actually use and never nets one against the other: what published trials and regulators say, graded A to F, and what people report online, counted and always shown with its sample size. No sellers, no sales links, no dosing advice. How to read this.

Search peptides by name, brand or goal

Filter by goal

• Sleep, 8 peptides
• Recovery & injury, 12 peptides
• Fat loss, 12 peptides
• Cognition & mood, 10 peptides
• Libido & sexual health, 3 peptides
• Longevity, 11 peptides
• Skin & hair, 5 peptides
• Immune, 5 peptides
• Muscle & strength, 7 peptides

Rank by goal in the goal finder →

44 of 44 peptides shown

• D

  5-Amino-1MQ

  Preclinical only · for fat loss and metabolism

  FDA Not approved WADA Likely prohibited (S0)
  User score 2.5
  Outcomes: Positive 10 of 22 (45%), Mixed 3 of 22 (14%), Negative 3 of 22 (14%), Unclear 6 of 22 (27%)
  Men 45–60: 0 · everyone: 22 reports · approximate
• D

  Adamax

  Preclinical only · for nootropic

  FDA Not approved WADA Likely prohibited (S0)
  User scoretoo few reports (4)
  Men 45–60: 0 · everyone: 4 reports · approximate
• D

  AHK-Cu

  Preclinical only · for topical or injected hair-growth use

  FDA Not approved WADA Not named
  User scoretoo few reports (3)
  Men 45–60: 0 · everyone: 3 reports · approximate
• F

  AOD-9604

  Tested and failed · for fat loss

  FDA Not approved WADA Prohibited (S2.2.3)
  User scoretoo few reports (6)
  Men 45–60: 0 · everyone: 6 reports · approximate
• C

  ARA-290

  Preliminary human data · for neuropathic pain / small-fibre nerve repair

  FDA Not approved WADA Prohibited (S2.1.5)
  User scoretoo few reports (5)
  Men 45–60: 0 · everyone: 5 reports · approximate
• C

  BPC-157

  Preliminary human data · for injury/tendon healing and gut repair (injected or oral)

  FDA Not approved WADA Prohibited (S0)
  User score 3.0
  Outcomes: Positive 12 of 21 (57%), Mixed 3 of 21 (14%), Negative 1 of 21 (5%), Unclear 5 of 21 (24%)
  Men 45–60: 3 · everyone: 21 reports · approximate
• A

  Bremelanotide

  Strong human evidence · for low sexual desire in premenopausal women (the approved use)

  FDA Approved: low desire in women WADA Not named
  User score 2.0
  Outcomes: Positive 2 of 15 (13%), Mixed 8 of 15 (53%), Negative 3 of 15 (20%), No effect 3 of 15 (20%)
  Men 45–60: 3 · everyone: 15 reports · approximate
• B

  Cerebrolysin

  Moderate human evidence · for cognitive and functional recovery in dementia, stroke rehabilitation and traumatic brain injury (the nationally authorised uses); healthy-person nootropic use is untested

  FDA Not approved WADA Not named
  User score 2.0
  Outcomes: Positive 4 of 13 (31%), Mixed 3 of 13 (23%), Negative 1 of 13 (8%), No effect 1 of 13 (8%), Unclear 4 of 13 (31%)
  Men 45–60: 0 · everyone: 13 reports · approximate
• C

  CJC-1295

  Preliminary human data · for raising growth hormone for body composition, recovery and sleep

  FDA Not approved WADA Prohibited (S2.2.4)
  User score 2.5
  Outcomes: Positive 6 of 12 (50%), Mixed 1 of 12 (8%), Negative 2 of 12 (17%), Unclear 3 of 12 (25%)
  Men 45–60: 1 · everyone: 12 reports · approximate
• C

  Delta sleep-inducing peptide

  Preliminary human data · for sleep

  FDA Not approved WADA Not named
  User score 4.0
  Outcomes: Positive 9 of 12 (75%), Mixed 1 of 12 (8%), Negative 1 of 12 (8%), Unclear 1 of 12 (8%)
  Men 45–60: 0 · everyone: 12 reports · approximate
• D

  Dihexa

  Preclinical only · for nootropic / cognitive repair

  FDA Not approved WADA Likely prohibited (S0)
  User scoretoo few reports (9)
  Men 45–60: 0 · everyone: 9 reports · approximate
• C

  Elamipretide

  Preliminary human data · for mitochondrial support / anti-ageing in people without Barth syndrome

  FDA Approved for Barth syndrome only WADA Not named
  User score 3.5
  Outcomes: Positive 11 of 21 (52%), Mixed 6 of 21 (29%), Negative 1 of 21 (5%), No effect 2 of 21 (10%), Unclear 1 of 21 (5%)
  Men 45–60: 0 · everyone: 21 reports · approximate
• C

  Epitalon

  Preliminary human data · for longevity, telomeres and sleep

  FDA Not approved WADA Likely prohibited (S0)
  User scoretoo few reports (8)
  Men 45–60: 0 · everyone: 8 reports · approximate
• D

  Follistatin-344

  Preclinical only · for injected protein for muscle growth

  FDA Not approved WADA Prohibited (S4.3)
  User scoretoo few reports (9)
  Men 45–60: 0 · everyone: 9 reports · approximate
• D

  FOXO4-DRI

  Preclinical only · for senolytic anti-ageing

  FDA Not approved WADA Likely prohibited (S0)
  User score 1.0
  Outcomes: Positive 2 of 11 (18%), Mixed 1 of 11 (9%), Negative 2 of 11 (18%), No effect 2 of 11 (18%), Unclear 4 of 11 (36%)
  Men 45–60: 0 · everyone: 11 reports · approximate
• C

  GHK-Cu

  Preliminary human data · for topical skin and hair cosmetic use (injectable 'systemic anti-ageing' has no human trials)

  FDA Not approved WADA Not named
  User score 3.5
  Outcomes: Positive 44 of 64 (69%), Mixed 5 of 64 (8%), Negative 4 of 64 (6%), No effect 4 of 64 (6%), Unclear 7 of 64 (11%)
  Men 45–60: 1 · everyone: 64 reports · approximate
• D

  Human growth hormone fragment 176–191

  Preclinical only · for fat loss (native-sequence hGH 176-191)

  FDA Not approved WADA Prohibited (S2.2.3)
  User score 2.5
  Outcomes: Positive 7 of 19 (37%), Mixed 5 of 19 (26%), Negative 1 of 19 (5%), No effect 2 of 19 (11%), Unclear 4 of 19 (21%)
  Men 45–60: 0 · everyone: 19 reports · approximate
• D

  Humanin

  Preclinical only · for longevity, metabolic and neuroprotective use

  FDA Not approved WADA Likely prohibited (S0)
  User scoretoo few reports (7)
  Men 45–60: 0 · everyone: 7 reports · approximate
• B

  Ibutamoren mesylate

  Moderate human evidence · for raising GH/IGF-1 and lean mass

  FDA Not approved WADA Prohibited (S2.2.4)
  User score 3.5
  Outcomes: Positive 18 of 29 (62%), Mixed 6 of 29 (21%), Negative 3 of 29 (10%), No effect 2 of 29 (7%), Unclear 1 of 29 (3%)
  Men 45–60: 1 · everyone: 29 reports · approximate
• D

  IGF-1 LR3

  Preclinical only · for muscle growth and recovery

  FDA Not approved WADA Prohibited (S2.3)
  User scoretoo few reports (6)
  Men 45–60: 0 · everyone: 6 reports · approximate
• C

  Ipamorelin

  Preliminary human data · for raising growth hormone for sleep and body composition

  FDA Not approved WADA Prohibited (S2.2.4)
  User score 4.0
  Outcomes: Positive 34 of 48 (71%), Mixed 8 of 48 (17%), Negative 4 of 48 (8%), No effect 2 of 48 (4%)
  Men 45–60: 2 · everyone: 48 reports · approximate
• C

  Khavinson bioregulators

  Preliminary human data · for general anti-ageing / organ 'bioregulation' (the family as a class)

  FDA Varies by substance WADA Varies by substance
  User score 3.0
  Outcomes: Positive 10 of 18 (56%), Mixed 1 of 18 (6%), Negative 1 of 18 (6%), No effect 3 of 18 (17%), Unclear 3 of 18 (17%)
  Men 45–60: 0 · everyone: 18 reports · approximate
• C

  Kisspeptin-10

  Preliminary human data · for testosterone / libido support

  FDA Not approved WADA Prohibited (S2.2.1)
  User score 4.0
  Outcomes: Positive 10 of 14 (71%), Mixed 2 of 14 (14%), No effect 1 of 14 (7%), Unclear 1 of 14 (7%)
  Men 45–60: 0 · everyone: 14 reports · approximate
• D

  KPV

  Preclinical only · for gut and skin anti-inflammatory use

  FDA Not approved WADA Likely prohibited (S0)
  User score 2.5
  Outcomes: Positive 11 of 32 (34%), Mixed 11 of 32 (34%), Negative 5 of 32 (16%), No effect 2 of 32 (6%), Unclear 3 of 32 (9%)
  Men 45–60: 0 · everyone: 32 reports · approximate
• D

  LL-37

  Preclinical only · for injected or nasal use for infections, biofilms and CIRS

  FDA Not approved WADA Prohibited (S0)
  User score 1.5
  Outcomes: Positive 4 of 23 (17%), Mixed 6 of 23 (26%), Negative 3 of 23 (13%), No effect 2 of 23 (9%), Unclear 6 of 23 (26%)
  Men 45–60: 0 · everyone: 23 reports · approximate
• C

  Melanotan II

  Preliminary human data · for tanning and erections

  FDA Not approved WADA Likely prohibited (S0)
  User score 3.5
  Outcomes: Positive 37 of 57 (65%), Mixed 11 of 57 (19%), Negative 9 of 57 (16%), Unclear 1 of 57 (2%)
  Men 45–60: 0 · everyone: 57 reports · approximate
• D

  MOTS-c

  Preclinical only · for metabolism, exercise performance and longevity

  FDA Not approved WADA Prohibited (S4.4.1)
  User score 2.5
  Outcomes: Positive 10 of 25 (40%), Mixed 7 of 25 (28%), Negative 4 of 25 (16%), No effect 3 of 25 (12%), Unclear 2 of 25 (8%)
  Men 45–60: 2 · everyone: 25 reports · approximate
• C

  Nicotinamide adenine dinucleotide, oxidized form

  Preliminary human data · for NAD+ infusions/injections for energy, cognition and anti-ageing

  FDA Not approved WADA Not named
  User score 2.5
  Outcomes: Positive 11 of 30 (37%), Mixed 6 of 30 (20%), Negative 8 of 30 (27%), No effect 1 of 30 (3%), Unclear 4 of 30 (13%)
  Men 45–60: 1 · everyone: 30 reports · approximate
• D

  PE-22-28

  Preclinical only · for mood and cognition

  FDA Not approved WADA Likely prohibited (S0)
  User score 2.0
  Outcomes: Positive 4 of 11 (36%), Mixed 1 of 11 (9%), Negative 4 of 11 (36%), No effect 2 of 11 (18%)
  Men 45–60: 0 · everyone: 11 reports · approximate
• D

  PEG-MGF

  Preclinical only · for muscle recovery and growth

  FDA Not approved WADA Prohibited (S2.3)
  User scoretoo few reports (7)
  Men 45–60: 1 · everyone: 7 reports · approximate
• C

  Pinealon

  Preliminary human data · for cognition, sleep and neuroprotection

  FDA Not approved WADA Likely prohibited (S0)
  User score 2.5
  Outcomes: Positive 4 of 10 (40%), Mixed 1 of 10 (10%), Negative 4 of 10 (40%), No effect 1 of 10 (10%), Unclear 1 of 10 (10%)
  Men 45–60: 0 · everyone: 10 reports · approximate
• C

  Rapamycin

  Preliminary human data · for longevity / healthy ageing (off-label, low intermittent dosing)

  FDA Approved for transplant & LAM only WADA Not named
  User scoretoo few reports (9)
  Men 45–60: 0 · everyone: 9 reports · approximate
• B

  Retatrutide

  Moderate human evidence · for weight loss

  FDA Not approved WADA Likely prohibited (S0)
  User score 3.0
  Outcomes: Positive 12 of 25 (48%), Mixed 7 of 25 (28%), Negative 3 of 25 (12%), Unclear 3 of 25 (12%)
  Men 45–60: 5 · everyone: 25 reports · approximate
• C

  Selank

  Preliminary human data · for anxiety relief

  FDA Not approved WADA Not named
  User score 3.0
  Outcomes: Positive 6 of 11 (55%), Mixed 1 of 11 (9%), Negative 1 of 11 (9%), No effect 2 of 11 (18%)
  Men 45–60: 0 · everyone: 11 reports · approximate
• A

  Semaglutide

  Strong human evidence · for weight management and type 2 diabetes

  FDA Approved WADA Not prohibited
  User score 4.0
  Outcomes: Positive 17 of 24 (71%), Mixed 6 of 24 (25%), Unclear 2 of 24 (8%)
  Men 45–60: 9 · everyone: 24 reports · approximate
• C

  Semax

  Preliminary human data · for nootropic / cognitive enhancement

  FDA Not approved WADA Not named
  User score 3.0
  Outcomes: Positive 29 of 61 (48%), Mixed 18 of 61 (30%), Negative 4 of 61 (7%), No effect 5 of 61 (8%), Unclear 5 of 61 (8%)
  Men 45–60: 0 · everyone: 61 reports · approximate
• C

  Sermorelin

  Preliminary human data · for adult growth-hormone 'optimisation', sleep and body composition

  FDA Approval withdrawn WADA Prohibited (S2.2.4)
  User score 2.0
  Outcomes: Positive 16 of 48 (33%), Mixed 10 of 48 (21%), Negative 16 of 48 (33%), No effect 3 of 48 (6%), Unclear 3 of 48 (6%)
  Men 45–60: 1 · everyone: 48 reports · approximate
• C

  SNAP-8

  Preliminary human data · for topical anti-wrinkle

  FDA Not approved WADA Not named
  User scoretoo few reports (8)
  Men 45–60: 0 · everyone: 8 reports · approximate
• D

  TB-500

  Preclinical only · for injected TB-500 fragment for injury recovery

  FDA Not approved WADA Prohibited (S2.3)
  User score 2.0
  Outcomes: Positive 4 of 11 (36%), Negative 3 of 11 (27%), No effect 2 of 11 (18%), Unclear 2 of 11 (18%)
  Men 45–60: 0 · everyone: 11 reports · approximate
• B

  Tesamorelin

  Moderate human evidence · for visceral / abdominal fat reduction in people without HIV

  FDA Approved for HIV-related belly fat only WADA Prohibited (S2.2.4)
  User score 2.5
  Outcomes: Positive 10 of 23 (43%), Mixed 4 of 23 (17%), Negative 6 of 23 (26%), No effect 1 of 23 (4%), Unclear 2 of 23 (9%)
  Men 45–60: 2 · everyone: 23 reports · approximate
• C

  Thymalin

  Preliminary human data · for immune 'rejuvenation', thymus regeneration and longevity

  FDA Not approved WADA Not named
  User scoretoo few reports (5)
  Men 45–60: 0 · everyone: 5 reports · approximate
• B

  Thymosin alpha-1

  Moderate human evidence · for immune support / infection defence

  FDA Not approved WADA Not named
  User scoretoo few reports (9)
  Men 45–60: 0 · everyone: 9 reports · approximate
• A

  Tirzepatide

  Strong human evidence · for weight management and type 2 diabetes

  FDA Approved WADA Not prohibited
  User score 4.0
  Outcomes: Positive 17 of 23 (74%), Mixed 5 of 23 (22%), Negative 1 of 23 (4%)
  Men 45–60: 8 · everyone: 23 reports · approximate
• C

  Vasoactive intestinal peptide

  Preliminary human data · for intranasal VIP for CIRS / chronic inflammation

  FDA Not approved WADA Not named
  User scoretoo few reports (9)
  Men 45–60: 0 · everyone: 9 reports · approximate

How to read this

Evidence grade (A–F)

How strong the human evidence is for the use named next to the grade — the use it is marketed for. Grades rate evidence, not safety.

User score (stars)

Share of positive reports (mixed counts half) among everyone who reported, as 1–5 stars. Shown only with 10 or more reports.

Men 45–60

Reports from men who state an age of 45 to 60. Always shown as “n of N”; percentages and charts only when N is 10 or more.

FDA · WADA · EU

US approval status, the World Anti-Doping Agency list, and an EU line when known — each with the date we checked.

Editorial ratings

The editors’ own judgement on a 0–5 scale. Labelled EDITORIAL because it is opinion, not data.

User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds. Full method.

A Strong human evidenceB Moderate human evidenceC Preliminary human dataD Preclinical onlyF Tested and failed